Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.

You may also be interested in...



Too Bold By Half: Allergan’s Latest Moves And Pharma’s Leadership Deficit

Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.

Drug Compounding Can't Be Justified By Price, FDA Says

Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.

Building A Foundation: Express Scripts’ Miller On Recent Outcomes-Based Contracts

In an interview, the PBM's chief medical officer discusses outcomes-based contracts, comments on whether the drug pricing debate will be impacted by slowing growth in drug spending, and notes an upcoming focus at the PBM on controlling diabetes drug costs

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel